Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 10, 2007, Pages 1990-1999

  Holick, Crystal N ^a,e   Stanford, Janet L ^a   Kwon, Erika M ^c   Ostrander, Elaine A ^c   Nejentsev, Sergey ^d   Peters, Ulrike ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e i3 Drug Safety   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALPHA HYDROXYLASE; OXYGENASE; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; CYP24A1 GENE; CYP27B1 GENE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 12; CYTOCHROME P-450 ENZYME SYSTEM; EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK ASSESSMENT; VARIATION (GENETICS);

EID: 35448993870     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0487     Document Type: Article

References (40)

1. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
2. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-72.
3. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-6.
4. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89-90:533-7.
5. Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-32.
6. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
7. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-8.
8. Polek TC, Weigel NL. Vitamin D and prostate cancer. J Androl 2002;23:9-17.
9. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006;102:156-62.
10. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:1395-402.
11. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006;175:1613-23.
12. Nejentsev S, Godfrey L, Snook H, et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004;13:1633-9.
13. Hawkins GA, Cramer SD, Zheng SL, et al. Sequence variants in the human 25-hydroxyvitamin D3 1-α-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 2002;53:175-8.
14. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:881-6.
15. Clayton D. Choosing a set of haplotype tagging SNPs from a larger set of diallelic loci. Available from: http://www-gene.cimr.cam.ac.uk/clayton/software/ stata/, 2005.
16. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. Nat Rev Genet 2004;5:89-100.
17. Haploview. Available from: http://www.broad.mit.edu/mpg/haploview/, 2006.
18. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
19. Hornik K. The R FAQ. Available from: http://CRAN.R-project.org/doc/FAQ/R- FAQ.html/, 2006.
20. Schaid DJ, Rowland CM. Robust transmission regression models for linkage and association. Genet Epidemiol 2000;19 Suppl 1:S78-84.
21. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
22. The SAS system for Windows, release 9.1. Cary (NC): SAS Institute; 2002.
23. Benjamini Y, Yukutieli D. False discovery-rate adjusted multiple confidence intervals for selected parameters (with discussion). J Am Stat Assoc 2005;100:71-93.
24. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58:277-88.
25. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7:391-5.
26. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1α-hydroxylase. J Clin Endocrinol Metab 2001;86:888-94.
27. Moon S, Holley S, Bodiwala D, et al. Associations between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Ann Hum Genet 2006;70:226-36.
28. Crescioli C, Maggie M, Vannelli GB, et al. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab 2000;85:2576-83.
29. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002;22:139-66.
30. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000;9:265-70.
31. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1α,25- dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000;6:901-8.
32. Hsu JY, Feldman D, McNeal JE, Peehl DM. Reduced 1a-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61:2852-6.
33. Whitlatch LW, Young MV, Schwartz GG, et al. 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 2002;81:135-40.
34. Baker MR, Peacock M, Nordin BE. The decline in vitamin D status with age. Age Ageing 1980;9:249-52.
35. Lawson DE, Paul AA, Black AE, Cole TJ, Mandal AR, Davie M. Relative contributions of diet and sunlight to vitamin D state in the elderly. Br Med J 1979;2:303-5.
36. Holick MF. Sunlight and vitamin D: the bone and cancer connections. Radiat Prot Dosimetry 2000;91:65-71.
37. Bodiwala D, Luscombe CJ, French ME, et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ Mol Mutagen 2004;43:121-7.
38. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4:e103.
39. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-90.
40. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990;10:1307-11.